The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.90
Bid: 1.80
Ask: 2.00
Change: 0.375 (24.59%)
Spread: 0.20 (11.111%)
Open: 1.525
High: 1.90
Low: 1.90
Prev. Close: 1.525
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

1 Jun 2023 11:00

RNS Number : 3512B
Shield Therapeutics PLC
01 June 2023
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Shield Therapeutics plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

x

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

x

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Nutrition-Wellness Venture SA

City and country of registered office (if applicable)

Vevey, Switzerland

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

16 March 2023 and 9 May 2023 (post AOP conversion)

6. Date on which issuer notified (DD/MM/YYYY):

25 May 2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

7.85%

0%

7.85%

56,008,541

Position of previous notification (if

applicable)

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BYV81293

56,008,541

0

7.85%

0%

SUBTOTAL 8. A

56,008,541

7.85%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

X

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Nestle S.A.

7.85%

7.85%

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

 

Place of completion

Vevey, Switzerland

Date of completion

31 May 2023

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFBMLTMTIMMPJ
Date   Source Headline
14th Sep 20207:00 amRNSNotice of Results
28th Aug 202012:21 pmRNSTotal Voting Rights Update
6th Aug 20202:21 pmRNSAEGIS-H2H study reanalysis
31st Jul 20207:00 amRNSTotal Voting Rights update
16th Jul 20207:00 amRNSPT20 paper publication
30th Jun 20207:00 amRNSTotal Voting Rights Update
26th Jun 20207:00 amRNSAppointment of Non-Executive Director
18th Jun 20203:18 pmRNSResults of 2020 Annual General Meeting
3rd Jun 20207:00 amRNSFeraccru®/Accrufer® publications
29th May 202011:25 amRNSTotal Voting Rights Update
28th May 20207:00 amRNSInvestor presentations
26th May 20207:00 amRNSAppointment of Chairman
22nd May 20204:15 pmRNS2019 Annual Report and 2020 AGM Notice
21st May 20204:40 pmRNSSecond Price Monitoring Extn
21st May 20204:35 pmRNSPrice Monitoring Extension
21st May 20207:00 amRNSPreliminary Results
19th May 20207:00 amRNSNotice of Results
11th May 20201:15 pmEQSHardman & Co Research: Shield Therapeutics (STX): Reassuring trading update
1st May 20207:00 amRNSBusiness and trading update
30th Apr 20205:23 pmRNSTotal Voting Rights Update
27th Apr 20207:00 amRNSFurther re. Directorate Change
22nd Apr 20207:00 amRNSDirectorate Change
26th Mar 20204:42 pmRNSSecond Price Monitoring Extn
26th Mar 20204:36 pmRNSPrice Monitoring Extension
20th Mar 202011:36 amRNSHolding(s) in Company
17th Mar 20202:06 pmRNSSecond Price Monitoring Extn
17th Mar 20202:00 pmRNSPrice Monitoring Extension
17th Mar 20207:00 amRNSAEGIS-H2H study update
6th Mar 20207:00 amRNSInvestor Presentation
2nd Mar 20204:41 pmRNSBlock Listing Application
21st Feb 202011:14 amRNSHolding(s) in Company
28th Jan 202012:15 pmEQSHardman & Co Research: Shield Therapeutics (STX): Good demand for Feraccru in Europe
27th Jan 20207:00 amRNSBusiness and trading update
24th Jan 20207:00 amRNSInvestor presentations
14th Jan 20207:15 amEQSHardman & Co Research: Shield Therapeutics (STX): Taking on China
8th Jan 20207:00 amRNSChina licence agreement for Feraccru/Accrufer
12th Dec 20195:30 pmRNSEland Oil & Gas
29th Nov 20193:31 pmRNSHolding(s) in Company
25th Nov 20197:00 amRNSQCA Corporate Governance Code
30th Oct 20197:30 amEQSHardman & Co Research: Shield Therapeutics (STX): More choice for clinicians and patients
22nd Oct 20197:00 amRNSPositive results presented at UEG Week 2019
26th Sep 20197:00 amRNSInvestor Presentation
2nd Sep 20199:14 amEQSHardman & Co Research: Shield Therapeutics (STX): FDA approval ushers in a new era for Shield
29th Aug 20197:00 amRNSInvestor presentations
15th Aug 201910:17 amRNSDirector/PDMR Shareholding
7th Aug 20197:00 amRNSHalf-year Report
5th Aug 201911:22 amEQSHardman & Co Research: Shield Therapeutics (STX) FDA approval opens door to major US opportunity
31st Jul 20191:21 pmRNSNotice of Results
26th Jul 20192:05 pmRNSSecond Price Monitoring Extn
26th Jul 20192:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.